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Immunity Induced by Inﬂ  uenza 
Virus Neuraminidase
The inﬂ  uenza virus major surface 
glycoproteins hemagglutinin (HA) and 
neuraminidase (NA) are the principal 
targets of the protective immune 
response. Licensed seasonal inﬂ  uenza 
virus vaccines are designed to elicit a 
protective immune response to the 
HA and NA proteins. However, only 
the concentration of HA protein is 
standardized in the currently approved 
inactivated seasonal inﬂ  uenza virus 
vaccines; the concentration of the 
NA protein is not. Hemagglutinin 
induces strain-speciﬁ  c neutralizing 
antibodies that prevent infection by 
antigenically related inﬂ  uenza viruses. 
Unlike HA-speciﬁ  c antibodies, NA-
speciﬁ  c antibodies do not prevent 
inﬂ  uenza virus infection, and NA 
immunity is referred to as infection 
permissive [1]. However, humoral 
immunity induced by NA can markedly 
reduce virus replication and release, 
shortening the severity and duration 
of illness, a reasonable goal in the 
event of an inﬂ  uenza pandemic [2,3]. 
In mice, the induction of a relatively 
modest NA-speciﬁ  c humoral response 
is sufﬁ  cient to inhibit virus replication 
after challenge with homologous 
inﬂ  uenza virus [4–6]. NA-speciﬁ  c 
immunity in mice provides signiﬁ  cant 
cross-protection against replication 
of antigenically distinct viruses of the 
same subtype (drift variants) but not 
against different subtypes [7]. The 
degree of relatedness between the NA 
used for immunization and that of the 
challenge virus correlates well with the 
degree of cross-protection conferred by 
an NA-speciﬁ  c response.
The emergence in 1968 of an 
H3N2 inﬂ  uenza virus with a novel HA 
subtype (H3) provided scientists with 
an opportunity to evaluate the role 
of NA-speciﬁ  c antibody in protection 
from inﬂ  uenza illness in humans. In a 
cohort of individuals with varying levels 
of N2-speciﬁ  c antibody, the severity of 
clinical illness correlated with the level 
of NA-speciﬁ  c serum antibody present 
at the time of virus challenge (H3N2) 
[3]. Ten of 11 men with serum NA 
inhibition antibody titers less than 1:4 
presented with afebrile or febrile illness 
following virus challenge, while one 
displayed no clinical signs of illness. In 
contrast, four of ten men with serum 
NA inhibition antibody titers greater 
than 1:4 presented with illness, while 
six displayed no sign of illness. These 
data suggest that NA antibody can 
modify the severity of illness associated 
with inﬂ  uenza. However, even when 
the NA was fully conserved between the 
previously circulating H2N2 virus and 
the newly emerged H3N2 virus, and NA 
immunity may have blunted the severity 
of the pandemic, it was not sufﬁ  cient 
to prevent morbidity and mortality 
associated with the 1968 inﬂ  uenza 
pandemic.
Does Human Inﬂ  uenza Virus 
NA-Speciﬁ  c Antibody Cross-React 
with Avian Inﬂ  uenza Virus NA?
Matthew Sandbulte and colleagues’ 
new ﬁ  ndings presented in PLoS Medicine 
provide a tantalizing suggestion that 
immunity to the human inﬂ  uenza virus 
N1 NA (huN1 NA) cross-reacts with 
the avian N1 NA (avN1 NA), and that 
this cross-reactivity may be sufﬁ  cient 
to protect against infection with avian 
inﬂ  uenza virus H5N1 [8]. H1N1 
inﬂ  uenza viruses have been circulating 
in the human population since 1977, 
and much of the population has 
encountered these viruses repeatedly, 
either through natural infection or 
vaccination. If huN1 NA antibodies can 
provide humans with cross-protection 
against avian inﬂ  uenza virus H5N1 
illness, introduction of this virus into 
the human population may cause less 
devastating morbidity and mortality 
than has been predicted [9].
Sandbulte and colleagues 
vaccinated mice with two doses of 
DNA encoding the NA protein of 
A/New Caledonia/20/99 (H1N1), 
one of the viruses in the currently 
recommended trivalent seasonal 
human inﬂ  uenza virus vaccine. 
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Data suggest that 
NA antibody can modify 
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Antibodies to the homologous huN1 
NA protein were detected in 91% of 
vaccinated mice, while only 13% of 
the mice had detectable cross-reactive 
antibodies to the avN1 NA protein 
of A/Vietnam/1203/04 (H5N1). 
However, the huN1 NA DNA vaccine 
provided a signiﬁ  cant degree of 
protection from lethal challenge 
with A/Vietnam/1203/04 (H5N1); 
lethality was reduced from 100% in 
mock-vaccinated mice to 50% in mice 
vaccinated with huN1 NA, and this 
was accompanied by a reduction in 
the severity of illness as measured 
by weight loss. A similar level of 
protection was observed when sera 
from vaccinated mice were transferred 
to naïve mice, suggesting that the 
protection was antibody-mediated. 
The effect of immunization with the 
huN1 NA DNA vaccine on replication 
of A/Vietnam/1203/2004 (H5N1) 
in the lungs or other organs was not 
examined.
To determine if a similar pattern of 
cross-reactivity of anti-NA antibodies 
occurs in humans, serum samples 
collected from human volunteers were 
assayed for huN1 NA and avN1 NA 
antibodies by neuraminidase inhibition 
assay. Inhibitory activity against 
the huN1 NA of inﬂ  uenza A/New 
Caledonia/20/99 (H1N1) was detected 
in 31 of 38 sera tested, and interestingly, 
inhibitory activity against the avN1 NA 
proteins of A/Hong Kong/213/03 
(H5N1) and A/Vietnam/1203/04 
(H5N1) were detected in eight of 38 
and nine of 38 individuals, respectively. 
Based on these ﬁ  ndings, the authors 
hypothesize that antibodies to the huN1 
NA induced by vaccines containing 
H1N1 inﬂ  uenza viruses or by natural 
infection with human inﬂ  uenza H1N1 
viruses could provide humans with some 
degree of protection against H5N1 
inﬂ  uenza viruses.
What Does This Study Mean 
for Pandemic Inﬂ  uenza 
Preparedness Efforts?
The important question raised by 
this study is whether N1 NA-speciﬁ  c 
antibodies can offer some level of 
protection against avian inﬂ  uenza 
H5N1 viruses. Sandbulte and 
colleagues clearly demonstrate that 
vaccination of mice with DNA encoding 
huN1 NA induces sufﬁ  cient humoral 
immunity to provide partial protection 
against H5N1 virus infection. They also 
provide evidence that approximately 
20% of the human population have 
anti-NA antibodies that cross-react at 
low titers with the avN1 NA.
The ﬁ  ndings of this study are very 
intriguing and should be investigated 
further, but the data are insufﬁ  cient to 
conclude that humans with huN1 NA 
humoral immunity will be protected 
against avian inﬂ  uenza virus H5N1 
infection. While previous studies clearly 
established that NA-speciﬁ  c antibodies 
can modulate the severity of inﬂ  uenza 
illness, the level of antibodies necessary 
to mediate such protection is not well 
established, and the low titer of cross-
reactive NA-speciﬁ  c antibody detected 
in humans in this study may not be 
sufﬁ  cient to protect against illness 
associated with avian inﬂ  uenza virus 
infection.
Additionally, although the NA 
was antigenically identical to that 
of the previously circulating H2N2 
inﬂ  uenza virus, the 1968 H3N2 
pandemic inﬂ  uenza virus caused 
severe morbidity and mortality. 
While NA antibodies cross-reactive 
with avN1 NA can be detected in the 
human population, the ability of these 
antibodies to reduce the morbidity 
and mortality of an H5N1 virus with an 
antigenically distantly related N1 NA 
may be minimal. It will not be easy to 
determine the cross-protective titer of 
N1 NA-speciﬁ  c antibodies in humans, 
because human infections by H5N1 
viruses are sporadic.
While the current HA-based human 
inﬂ  uenza vaccines are efﬁ  cacious 
when the epidemic strain matches 
the vaccine strain, consideration of 
the other viral proteins as targets 
for the development of pandemic 
inﬂ  uenza virus vaccines is prudent. 
We cannot predict which strain of 
avian inﬂ  uenza virus will cross the 
species barrier and cause a pandemic 
and, therefore, it is unlikely that the 
vaccine strains selected will exactly 
match the pandemic virus. In addition, 
avian inﬂ  uenza HA proteins are less 
immunogenic than human inﬂ  uenza 
HA proteins, requiring two doses of 
vaccine to induce antibody titers that 
correlate with protection from human 
inﬂ  uenza [10–14].
Are the data from the study by 
Sandbulte and colleagues sufﬁ  ciently 
promising to recommend widespread 
use of human inﬂ  uenza vaccines to 
induce NA-speciﬁ  c antibodies in the 
hope that cross-reactive antibodies 
will protect from H5N1 infection? 
The concentration of NA in licensed 
inactivated human inﬂ  uenza virus 
vaccines is not standardized, and the 
correlation between this concentration 
and resulting titers of NA antibodies 
in vaccine recipients is not known. NA-
speciﬁ  c immunity is difﬁ  cult to study, 
because it is difﬁ  cult to separate the 
effects of NA-speciﬁ  c immunity from 
immunity induced by the HA and other 
inﬂ  uenza virus proteins.
Some of these questions could be 
addressed if studies were carried out 
using different vaccine formulations 
with known concentrations of NA in 
study populations stratiﬁ  ed by anti-HA 
antibody titers. Additionally, the ability 
of live attenuated inﬂ  uenza vaccines to 
induce anti-NA antibodies should be 
investigated, an approach adopted in 
a study by the late Mary Lou Clements 
and her colleagues [15]. One might 
then be able to select a vaccine that 
induces the highest-titer NA antibody 
response; the more closely related the 
NA of the vaccine virus and pandemic 
virus, the greater the potential beneﬁ  t 
of such an approach will be. If further 
research supports the ﬁ  ndings from 
the current PLoS Medicine study and 
widespread vaccination with human 
inﬂ  uenza virus vaccines is undertaken, 
the supply of embryonated eggs could 
become a limiting factor if efforts 
to immunize large populations with 
vaccines containing human inﬂ  uenza 
A H1N1 viruses are undertaken while 
H5N1 inﬂ  uenza vaccines are also 
being stockpiled. However, widespread 
vaccination with licensed human 
inﬂ  uenza virus vaccines could occur 
more rapidly than with pandemic 
inﬂ  uenza vaccines that are still under 
development.
Until the extent and biological 
beneﬁ  t of cross-reactive N1 NA 
immunity is investigated further, it is 
premature to conclude that immunity 
induced by the human inﬂ  uenza 
virus N1 NA will provide signiﬁ  cant 
protection from illness associated with 
avian inﬂ  uenza H5N1 virus infection.  
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